Optimized AAV capsids for basal ganglia diseases show robust potency and distribution
Open Access
- 19 May 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Abstract
Huntington’s disease and other disorders of the basal ganglia create challenges for biomolecule-based medicines given the poor accessibility of these deep brain structures following intracerebral or intravascular delivery. Here, we found that low dose, low volume delivery of unbiased AAV libraries into the globus pallidus allowed recovery of novel capsids capable of broad access to key deep brain and cortical structures relevant for human therapies. One such capsid, AAV-DB-3, provided transduction of up to 45% of medium spiny neurons in the adult NHP striatum, along with substantial transduction of relevant deep layer neurons in the cortex. Notably, AAV-DB-3 behaved similarly in mice as in NHPs and potently transduced human neurons derived from induced pluripotent stem cells. Thus, AAV-DB-3 provides a unique AAV for network level brain gene therapies that translates up and down the evolutionary scale for preclinical studies and eventual clinical use.Keywords
Funding Information
- Children's Hospital of Philadelphia
This publication has 50 references indexed in Scilit:
- Reproducible Differentiation of Human Pluripotent Stem Cells into Two‐Dimensional Cortical Neuron Cultures with Checkpoints for SuccessCurrent Protocols, 2023
- Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNSMed, 2022
- High-resolution mapping and digital atlas of subcortical regions in the macaque monkey based on matched MAP-MRI and histologyNeuroImage, 2021
- Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune ActivationNeuron, 2020
- Transcription Factor–Mediated Differentiation of Human iPSCs into NeuronsCurrent Protocols in Cell Biology, 2018
- AAV viral vector delivery to the brain by shape-conforming MR-guided infusionsJournal of Controlled Release, 2016
- PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington’s Disease-Associated Phenotypes In VivoNeuron, 2016
- Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem CellsNeuron, 2013
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993